Cambridge Investment Research Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13M | Buy |
68,967
+2,818
| +4% | +$530K | 0.03% | 562 |
|
|
2026
Q1 | $12.9M | Buy |
66,149
+2,632
| +4% | +$507K | 0.03% | 520 |
|
|
2025
Q4 | $11.7M | Buy |
63,517
+2,032
| +3% | +$356K | 0.03% | 523 |
|
|
2025
Q3 | $9.43M | Buy |
61,485
+1,900
| +3% | +$288K | 0.03% | 586 |
|
|
2025
Q2 | $8.33M | Buy |
59,585
+2,102
| +4% | +$295K | 0.03% | 619 |
|
|
2025
Q1 | $8.45M | Buy |
57,483
+12,983
| +29% | +$1.88M | 0.03% | 571 |
|
|
2024
Q4 | $5.83M | Sell |
44,500
-1,737
| -4% | -$243K | 0.02% | 718 |
|
|
2024
Q3 | $7.21M | Sell |
46,237
-1,801
| -4% | -$291K | 0.02% | 622 |
|
|
2024
Q2 | $7.49M | Buy |
48,038
+3,172
| +7% | +$477K | 0.03% | 575 |
|
|
2024
Q1 | $6.08M | Sell |
44,866
-3,851
| -8% | -$510K | 0.02% | 650 |
|
|
2023
Q4 | $6.56M | Sell |
48,717
-4,028
| -8% | -$524K | 0.03% | 575 |
|
|
2023
Q3 | $7.14M | Buy |
52,745
+5,051
| +11% | +$690K | 0.03% | 498 |
|
|
2023
Q2 | $6.83M | Sell |
47,694
-343
| -0.7% | -$50.5K | 0.03% | 515 |
|
|
2023
Q1 | $6.67M | Buy |
48,037
+486
| +1% | +$65.4K | 0.03% | 498 |
|
|
2022
Q4 | $6.45M | Buy |
47,551
+2,342
| +5% | +$294K | 0.03% | 498 |
|
|
2022
Q3 | $4.96M | Buy |
45,209
+181
| +0.4% | +$23K | 0.03% | 573 |
|
|
2022
Q2 | $5.95M | Buy |
45,028
+1,499
| +3% | +$197K | 0.03% | 512 |
|
|
2022
Q1 | $5.78M | Sell |
43,529
-2,507
| -5% | -$301K | 0.03% | 571 |
|
|
2021
Q4 | $5.36M | Sell |
46,036
-4,635
| -9% | -$545K | 0.02% | 613 |
|
|
2021
Q3 | $6.09M | Buy |
50,671
+10,940
| +28% | +$1.27M | 0.03% | 526 |
|
|
2021
Q2 | $4.76M | Sell |
39,731
-13,680
| -26% | -$1.5M | 0.02% | 637 |
|
|
2021
Q1 | $5.31M | Sell |
53,411
-23,117
| -30% | -$2.32M | 0.03% | 537 |
|
|
2020
Q4 | $7.65M | Buy |
76,528
+27,021
| +55% | +$2.86M | 0.04% | 381 |
|
|
2020
Q3 | $5.43M | Buy |
49,507
+2,917
| +6% | +$324K | 0.04% | 437 |
|
|
2020
Q2 | $4.93M | Buy |
46,590
+5,070
| +12% | +$524K | 0.04% | 445 |
|
|
2020
Q1 | $3.71M | Buy |
41,520
+7,701
| +23% | +$725K | 0.04% | 457 |
|
|
2019
Q4 | $3.37M | Buy |
33,819
+1,732
| +5% | +$163K | 0.03% | 600 |
|
|
2019
Q3 | $2.86M | Buy |
32,087
+286
| +0.9% | +$24.8K | 0.03% | 620 |
|
|
2019
Q2 | $2.63M | Sell |
31,801
-763
| -2% | -$59.8K | 0.02% | 614 |
|
|
2019
Q1 | $2.63M | Buy |
32,564
+7,981
| +32% | +$629K | 0.03% | 609 |
|
|
2018
Q4 | $1.87M | Buy |
24,583
+79
| +0.3% | +$6.17K | 0.02% | 662 |
|
|
2018
Q3 | $1.94M | Buy |
24,504
+401
| +2% | +$30.3K | 0.02% | 698 |
|
|
2018
Q2 | $1.69M | Sell |
24,103
-2,231
| -8% | -$161K | 0.02% | 712 |
|
|
2018
Q1 | $1.84M | Buy |
26,334
+2,650
| +11% | +$184K | 0.02% | 652 |
|
|
2017
Q4 | $1.64M | Buy |
23,684
+2,130
| +10% | +$144K | 0.02% | 656 |
|
|
2017
Q3 | $1.46M | Sell |
21,554
-58
| -0.3% | -$3.66K | 0.02% | 654 |
|
|
2017
Q2 | $1.47M | Buy |
+21,612
| New | +$1.41M | 0.02% | 632 |
|
|
2016
Q4 | – | Sell |
-21,459
| Closed | -$1.41M | – | 1705 |
|
|
2016
Q3 | $1.41M | Buy |
+21,459
| New | +$1.4M | 0.03% | 541 |
|
|
2016
Q2 | – | Sell |
-18,674
| Closed | -$1.05M | – | 1591 |
|
|
2016
Q1 | $1.05M | Sell |
18,674
-528
| -3% | -$31.7K | 0.02% | 553 |
|
|
2015
Q4 | $1.3M | Buy |
+19,202
| New | +$1.26M | 0.03% | 472 |
|
|
2015
Q3 | – | Sell |
-14,943
| Closed | -$952K | – | 1471 |
|
|
2015
Q2 | $952K | Buy |
14,943
+452
| +3% | +$30.9K | 0.03% | 523 |
|
|
2015
Q1 | $992K | Buy |
14,491
+1,595
| +12% | +$111K | 0.03% | 509 |
|
|
2014
Q4 | $908K | Buy |
12,896
+1,714
| +15% | +$123K | 0.03% | 525 |
|
|
2014
Q3 | $799K | Buy |
11,182
+14
| +0.1% | +$1.02K | 0.02% | 594 |
|
|
2014
Q2 | $830K | Sell |
11,168
-2,356
| -17% | -$170K | 0.03% | 519 |
|
|
2014
Q1 | $877K | Sell |
13,524
-717
| -5% | -$46.3K | 0.03% | 470 |
|
|
2013
Q4 | $845K | Sell |
14,241
-3,515
| -20% | -$191K | 0.03% | 453 |
|
|
2013
Q3 | $922K | Buy |
17,756
+1,022
| +6% | +$51.3K | 0.04% | 384 |
|
|
2013
Q2 | $792K | Buy |
+16,734
| New | +$852K | 0.04% | 382 |
|
Other funds holding AZN
EP
IA
Cambridge Investment Research Advisors's AZN Position: Q2 2026 in Review
Cambridge Investment Research Advisors increased its AstraZeneca (AZN) stake by 4.3% in Q2 2026, buying an estimated $530K and bringing the position to 68,967 shares worth $13M. The position accounts for 0.03% of the portfolio, ranked #562.
Cambridge Investment Research Advisors first reported a position in AZN in Q2 2013 and has held it in 49 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Cambridge Investment Research Advisors held 68,967 shares of AstraZeneca worth $13M as of Q2 2026.
- Cambridge Investment Research Advisors bought 2,818 AstraZeneca shares in Q2 2026, an estimated $530K.
- AstraZeneca made up 0.03% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #562 holding.
- Cambridge Investment Research Advisors first reported a position in AstraZeneca in Q2 2013 and has held it in 49 quarters since.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.